Unravelling the tumour suppressor network in models of lung cancer

Unravelling the tumour suppressor network in models of lung cancer

Project details

Lung cancer is the leading cause of cancer deaths worldwide. Lung adenocarcinoma is the most common subtype of lung cancer with 35 per cent of cancers associated with oncogenic driver mutations in KRAS (TCGA, Nature 2014 511(7511):320). Mutations in the tumour suppressor genes TP53 and KEAP1 often co-occur with KRAS mutations, but are largely mutually exclusive (Skoulidis, Cancer Discovery 2015 5(8):860). This project will utilize sophisticated in vivo and in vitro approaches to explore TP53-dependent and independent mechanisms of KrasG12D-induced cancer development. 

This project will involve the use of a wide variety of experimental techniques, including pre-clinical models of lung cancer, tissue/tumour pathology, CRISPR-Cas9 gene-editing technology, next-generation sequencing, molecular biology, cell culture, microscopy and flow cytometry

About our research group

The Sutherland laboratory is embedded within the ACRF Cancer Biology and Stem Cells division and has a strong background in in vivo models of lung cancer. We have made seminal contributions into the identification of the cell-of-origin of lung cancer (Sutherland, PNAS 2014 111(13):4952; Sutherland, Cancer Cell 2011 19(6):754; Sutherland, Mol Oncol. 2010 4(5):397) and have a strong interest in identifying novel oncogenes and tumour suppressor genes in lung cancer development (Best, Oncogene 2018; Best, Cell Metabolism 2018 27(4):935).  

The Herold laboratory is part of the Blood Cells and Blood Cancer division and has a strong background in finding novel tumour suppressor and promoting genes in vitro and in vivo using CRISPR/Cas9 technology. We have substantially contributed to the identification and targeting of critical p53 regulated pathways (Janic, Nat Med. 2018 Jun 11) and survival factors important in sustained tumour growth, respectively (Kotschy, Nature. 2016 538(7626):477; Aubrey, Cell Reports 2015 10(8):1422; Kelly, Genes Dev. 2014 28(1):58). 


Dr Kate Sutherland

Kate Sutherland in a laboratory
Laboratory Head
Dr Sarah Best in the lab
ACRF Cancer Biology & Stem Cells division

Project Type: